🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2026-526397-17-00
Authorised Phase I

An open label, randomized, single-dose, two-treatment, two-sequence, two-period, cross-over pilot comparative bioavailability study comparing Empagliflozin and Metformin f.c. tabs (12.5+1000) mg, VIANEX S.A., Greece versus Synjardy 12.5 mg/1,000 mg film-coated tablets, Boehringer Ingelheim International GmbH, Germany, in healthy male and female volunteers under fasting conditions.

2026-526397-17-00 · tracked via the Priya Life Science EU tracker
Sponsor
Vianex S.A.
Sponsor type
Pharmaceutical company
Therapeutic area
Hormonal diseases
Decision date
05/08/2026
Enrollment target
18
Sites
Czechia

Condition studied

treatment of diabetes

Eligibility

Age group
18-64 years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2026-526397-17-00 on CTIS ↗ ← All trials in the EU